The leading European pharmaceutical marketplace now hosts more than 85 000 CTD dossiers for finished dosage formulation products. Compared to 19 600 products at the start of 2021, the product offering has increased fourfold over a single year. As a response to increasing demand, Pipelinepharma will introduce biosimilar drugs into a separate category. New finished dosage form categories for medical devices and nutraceuticals will also be launched in the coming months. “We are building upon our vision to become the world’s leading B2B pharma product platform. While quantity is sometimes a quality in itself, our product listings are curated by
The post Pipelinepharma marketplace records quadruple growth over a single year appeared first on Pharma Mirror Magazine.
